.jpg?n=5702 "ByrneWallace Logo")
Tom Maher - Partner
Tom joined the firm as a partner in the Corporate Department in 2010. He is a seasoned transactional life sciences lawyer with over 15 years experience in the international life sciences industry, split evenly between high profile industry positions and large Dublin law firms. Most recently, since 2005, Tom held the position of General Counsel at Amarin Corporation plc (AMRN), a NASDAQ listed biopharmaceutical company with a potential blockbuster drug in phase 3 trials in cardiovascular disease. He also held the position of Vice President, Legal Affairs at Elan Corporation plc (ELN) from 1997 to 2003. Between Elan and Amarin, he was a partner and Head of Life Sciences at another large Dublin law firm. Tom has acted for a broad range of clients across various sectors of the life sciences industry, including multinational pharmaceutical and medical technology companies, established indigenous biotech companies and leading university spin-out companies.
He specialises in corporate, partnering and commercial transactions and advice for life sciences clients, including research and development alliances, collaboration and partnering transactions, private equity/venture capital and mergers and acquisitions.
Life sciences brochure
Click here to download our life sciences brochure.
Representative transactions at Amarin
- Amarin’s capital fundraisings from 2005 to 2009 in excess of $150m, primarily through US financings to US and ex-US investors, including the $70m equity private placement to US and European VC funds and others in late 2009. The VC funds included Abingworth, Orbimed, Sofinnova, Longitude and Fountain
- Dual listing of Amarin on AIM and IEX in 2006 and subsequent de-listing from both exchanges in 2008
- Acquisition by Amarin of Ester Neurosciences Ltd (Israel) in 2007 for $32m in a complex cross-border transaction. The purchase consideration was Amarin ADSs issued ex-US under Regulation S of the US securities legislation
- Re-negotiation of license agreements between Ester Neurosciences and the University of Jerusalem
- Acquisition by Amarin of a novel formation of apomorphine for Parkinsons disease from the originator
- Development and License Agreement between Amarin and Elan Corporation plc for a nasal formulation of lorazepam for epilepsy and subsequent sale back of rights to Elan
- Supply Agreement between Amarin and Nisshin Pharma Inc (Japan) for the supply of the API for Amarin’s lead compound, AMR101
- Clinical trial agreements with Medpace for the multicenter Phase III clinical trials of AMR101 in cardiovascular disease, including Clinical Investigator Agreements, indemnity and other agreements in multiple jurisdictions.
Representative transactions prior to Amarin
- Acted for Elan in multiple US restructuring transactions
- Represented Opsona Therapeutics in its spin-out from Trinity College Dublin and its initial venture capital fundraising from Seroba, Inventages and Enterprise Ireland. Also acted for Opsona in partnering transactions, including the Opsona/Wyeth TLR collaboration transaction
- Respresented Wyeth US in strategic R&D collaboration work in Ireland with various universities, hospitals and other public bodies.
Qualifications
- LLB, Trinity College Dublin, 1989
- Qualified as a Solicitor, 1992